Your session is about to expire
← Back to Search
Other
Low-Fat High-Fiber Diet for Crohn's Disease
N/A
Waitlist Available
Led By Maria T Abreu, MD
Research Sponsored by University of Miami
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Documented diagnosed of Crohn's Disease
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 36
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a low-fat, high-fiber diet to help people with stomach problems and inflammation feel better.
Who is the study for?
This trial is for adults aged 18-70 with Crohn's Disease who have mild to moderate symptoms (sCDAI <400). They must not have used antibiotics or probiotics within the last two weeks and should be on stable doses of certain medications. Participants need to live with someone involved in their daily diet and can only be on low doses of steroids.
What is being tested?
The study tests a low-fat, high-fiber diet (LFD) designed to reduce gastrointestinal symptoms and inflammation in Crohn's patients. It includes Dyadic Psychological Support (DPS) and Diet Counseling to help participants adhere to the dietary changes.
What are the potential side effects?
While specific side effects are not listed for this dietary intervention, some individuals may experience changes in digestion or bowel habits as they adjust to the new diet.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with Crohn's Disease.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 36
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 36
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in fat intake
Rate of adherence to fat intake
Secondary study objectives
Change in clinical symptoms as assessed by Patient Reported Outcomes (PRO2).
Change in clinical symptoms as assessed by the Harvey Bradshaw Index (HBI)
Change in clinical symptoms as assessed by the Short Crohn's Disease Activity Index (sCDAI).
+4 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: Experimental CD Low Fat Diet (LFD) GroupExperimental Treatment1 Intervention
Participants will be provided catered LFD meals for 8 consecutive weeks consisting of daily breakfast, lunch, dinner and snacks.
Group II: Experimental CD LFD + DPS GroupExperimental Treatment2 Interventions
Participants and one family member that lives with them will be provided catered LFD meals for 8 consecutive weeks consisting of daily breakfast, lunch, dinner and snacks. In addition, the participant and their family member will receive 12 consecutive weeks of Dyadic Psychological Support (DPS).
Group III: Crohn's Disease (CD) Control GroupActive Control1 Intervention
Participants will receive only the one time standard of care in-clinic diet counseling at visit 1.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dyadic Psychological Support (DPS)
2019
N/A
~300
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Crohn's Disease include dietary interventions, medications, and sometimes surgery. A low-fat, high-fiber diet aims to reduce inflammation and improve gut health by minimizing fat intake, which can exacerbate inflammation, and increasing fiber intake, which promotes healthy gut bacteria and bowel movements.
This dietary approach can help manage symptoms and improve quality of life. Medications such as anti-inflammatory drugs, immunosuppressants, and biologics work by reducing inflammation and modulating the immune system to prevent flare-ups.
These treatments are essential for Crohn's Disease patients as they help control symptoms, maintain remission, and prevent complications.
Find a Location
Who is running the clinical trial?
The Leona M. and Harry B. Helmsley Charitable TrustOTHER
65 Previous Clinical Trials
99,265 Total Patients Enrolled
University of MiamiLead Sponsor
949 Previous Clinical Trials
428,164 Total Patients Enrolled
Maria T Abreu, MDPrincipal InvestigatorUniversity of Miami
1 Previous Clinical Trials
51 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have been diagnosed with Crohn's Disease.I am between 18 and 70 years old and live with someone who shares my daily meals.Your Crohn's disease activity score is too low to be included in the study.I have been on a stable dose of TNFs or immunosuppressants for at least 4 weeks.I haven't taken antibiotics or probiotics in the last 2 weeks.I have been taking the same dose of my ulcerative colitis medication for at least 2 weeks.I am taking no more than 20 mg of prednisone or 9 mg of budesonide daily.
Research Study Groups:
This trial has the following groups:- Group 1: Crohn's Disease (CD) Control Group
- Group 2: Experimental CD Low Fat Diet (LFD) Group
- Group 3: Experimental CD LFD + DPS Group
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger